NASDAQ:COGT Cogent Biosciences Q3 2024 Earnings Report $32.31 +0.88 (+2.80%) Closing price 09/25/2026 04:00 PM EasternExtended Trading$32.37 +0.06 (+0.20%) As of 09/25/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Cogent Biosciences EPS ResultsActual EPS-$0.64Consensus EPS -$0.57Beat/MissMissed by -$0.07One Year Ago EPS-$0.64Cogent Biosciences Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ACogent Biosciences Announcement DetailsQuarterQ3 2024Date11/12/2024TimeBefore Market OpensConference Call DateTuesday, November 12, 2024Conference Call Time7:00AM ETUpcoming EarningsCogent Biosciences' Q3 2026 earnings is estimated for Friday, November 6, 2026, based on past reporting schedules, with a conference call scheduled on Monday, November 2, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Cogent Biosciences Earnings HeadlinesCogent Biosciences (COGT) Stock Trades At A Premium As FDA Accepts NDASeptember 25 at 7:41 AM | finance.yahoo.comWill FDA’s Streamlined Bezuclastinib Review in ASM Change Cogent Biosciences’ (COGT) Narrative?September 24 at 3:09 PM | finance.yahoo.comDid you forget to grab this?Most beginners stay stuck on the sidelines for years because no one shows them the simple steps between being interested in options and actually placing a trade. Your First Trade Playbook closes that gap in one evening - and right now it is still free. Bill Poulos plans to charge for it soon, so download your copy before the temporary link expires.September 26 at 1:00 AM | Profits Run (Ad)Cogent Biosciences (COGT) Looks Fully Valued Following FDA NDA AcceptanceSeptember 24 at 3:09 PM | finance.yahoo.comWedbush Reaffirms Outperform Rating for Cogent Biosciences (NASDAQ:COGT)September 18, 2026 | americanbankingnews.comHC Wainwright Reaffirms Buy Rating for Cogent Biosciences (NASDAQ:COGT)September 17, 2026 | americanbankingnews.comSee More Cogent Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Cogent Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cogent Biosciences and other key companies, straight to your email. Email Address About Cogent BiosciencesCogent Biosciences (NASDAQ:COGT) is a clinical-stage biotechnology company focused on developing precision medicines for genetically defined diseases. The company uses its research platform to discover and advance targeted therapies designed to address the underlying drivers of serious medical conditions. Cogent’s lead product candidate is bezuclastinib, an oral, highly selective tyrosine kinase inhibitor designed to target the KIT D816V mutation and other KIT alterations. The company is developing bezuclastinib for systemic mastocytosis, a rare disorder involving the abnormal accumulation of mast cells, including both non-advanced and advanced forms of the disease. Cogent Biosciences is headquartered in Boulder, Colorado, and conducts its clinical development activities through studies involving patients and research sites in multiple regions. The company is led by Andrew Robbins, who serves as president and chief executive officer.View Cogent Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 09/21 - 09/25Costco Ends Its Fiscal Year on a High Note, Eyes Big ExpansionCracker Barrel Stock Is Rallying Again, But the Turnaround Still Has a Traffic ProblemSuper Micro’s Vera Rubin Shipments Put Its AI Infrastructure Advantage to the TestHims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks3 Space Stocks to Watch as SpaceX Reshapes the Launch MarketOil May Be Stronger Than It Looks—And Diamondback Is on Sale Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
